text: Rilpivirine is a DAPY compound like etravirine and was discovered when further optimization within this family of NNRTIs was conducted. The resistance profile and the genetic barrier to the development of resistance is comparable to etravirine in vitro. The advantage of rilpivirine over etravirine is a better bioavailability and it is easier to formulate than etravirine. Etravirine has required extensive chemical formulation work due to poor solubility and bioavailability. Rilpivirine was approved by the FDA for HIV therapy in May 2011 under the brand name Edurant. Edurant is approved for treatment-naive patients with a viral load of 100,000 copies/mL or less at therapy initiation. Its recommended dosage is 25 mg orally once daily with a meal, in combination with other antiretrovirals.  It is contraindicated for use with proton pump inhibitors due to the increased gastric pH causing decreased rilpivirine plasma concentrations, potentially resulting in loss of virologic response and possible resistance. A fixed-dose drug combining rilpivirine with emtricitabine and tenofovir disoproxil (TDF), was approved by the U.S. Food and Drug Administration in August 2011 under the brand name Complera. A newer fixed-dose drug also combining rilpivirine with emtricitabine and tenofovir alafenamide (TAF) was approved in March 2016 under the brand name Odefsey.